Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

Momelotinib in VEXAS Syndrome

This research study is looking at a new drug called momelotinib for people who have VEXAS syndrome, a rare inflammatory condition, sometimes alongside a blood disorder called myelodysplastic syndrome (MDS). The main goal is to find out if momelotinib is safe and if it helps improve VEXAS symptoms and MDS features. The first part of the study will find the right dose of momelotinib. Then, more patients will receive this dose, along with their usual steroid medication. Doctors will carefully monitor participants to see how they respond to the treatment and to check for any side effects over several months.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
Groupe Francophone des Myelodysplasies
Meta de inscrição
57
Iniciar
25 Nov 2025
Conclusão estimada
01 Nov 2028

Sobre o que é este estudo?

This study is for people living with a rare condition called VEXAS syndrome. VEXAS can cause ongoing inflammation throughout the body and often requires treatment with steroids. Some people with VEXAS also have a blood disorder called myelodysplastic syndrome (MDS). We are testing a new drug, momelotinib, to see if it can help manage VEXAS symptoms and potentially improve MDS features.

Momelotinib is a type of medication that works differently from steroids. We hope it might be an effective treatment for VEXAS, especially for those who rely heavily on steroids or whose symptoms aren't fully controlled. The study is divided into two main parts. The first part is designed to safely find the best dose of momelotinib. A small number of patients will receive different doses to see which one is most tolerable.

Once the safest and most effective dose is found, more patients will be invited to join the second part of the study. Everyone in the study will continue to take their steroid medication, as determined by their doctor, alongside momelotinib. Doctors will watch closely to see if momelotinib helps improve symptoms like inflammation and if it has any positive effects on MDS. We will also be carefully monitoring for any side effects to ensure the treatment is safe.

Pontos principais

  • This study is for VEXAS syndrome, with or without a blood condition (MDS).
  • It tests a new drug called momelotinib.
  • Participants will also continue taking their prescribed steroid medication.
  • The study has two parts: finding the right dose, then giving it to more patients.
  • Your health will be closely monitored with regular check-ups.
  • Você pode parar de participar a qualquer momento.

Quem pode ser elegível?

To be considered for this study, you must be at least 18 years old and have a confirmed diagnosis of VEXAS syndrome with a specific genetic change (UBA1 mutation). Your VEXAS symptoms should be active and currently require daily steroid treatment of at least 10mg. You might be eligible if your current treatments, including steroids, aren't fully controlling your symptoms, or if you find yourself needing higher and higher doses of steroids.

There are also some health checks you'll need to pass. For instance, your liver and kidney functions must be within certain healthy limits. If you are taking other medications that affect your immune system, you might need a short break from them before starting momelotinib. Certain growth factor treatments for blood conditions are also not allowed shortly before the study. We will check your overall health to make sure you are well enough to participate.

If you are a woman who could become pregnant, you'll need to have a negative pregnancy test and agree to use effective contraception throughout the study and for 12 weeks afterwards. If you are a man, you’ll also need to use a condom if you have sexual activity with a woman who could become pregnant. These steps are important to prevent pregnancy during the study because the effects of momelotinib on a developing baby are not known.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have a confirmed VEXAS syndrome diagnosis with the UBA1 genetic change?
  3. Are your VEXAS symptoms active and currently require at least 10mg of steroids daily?
  4. Are your liver and kidney functions generally healthy?
  5. If you are a woman who could get pregnant, are you willing to use effective contraception?
  6. If you are a man, are you willing to use a condom if having sexual activity with a woman who could get pregnant?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you will first go through a screening period to check if you're a good fit. During this time, your doctor will carefully decide the right dose of steroids you need daily to manage your VEXAS symptoms. Once you start treatment, you will take momelotinib every day at a dose determined by the study, along with your prescribed steroids.

Your health will be regularly monitored with hospital visits. Doctors will evaluate your VEXAS symptoms after 4, 12, 24, and 48 weeks. If you also have MDS, those features will be checked at 12 and 24 weeks. You will continue taking momelotinib until your VEXAS symptoms worsen, you no longer respond to the treatment, or if the doctors decide, in your best interest, to stop it. If the treatment isn't helping after 24 weeks at the optimal dose, it will be stopped. The study involves regular check-ups and medication, potentially for many months, but you can choose to leave the study at any time.

Riscos e benefícios potenciais

Taking part in this study may offer potential benefits, such as receiving a new and experimental treatment (momelotinib) that might help control your VEXAS symptoms and potentially improve MDS features, especially if your current treatments aren't fully effective. However, as with any new medication, there are potential risks and side effects that we don't fully know yet. These will be closely monitored, and your study doctor will discuss what is currently known. Your health will be carefully watched throughout the study. Remember, joining this study is completely voluntary, and you have the right to withdraw at any time, for any reason, without it affecting your usual medical care.

Localizações (11)

  • CHU d'Angers - Service des Maladies du sang
    Código postal verificado
    Angers, França· Ainda não recrutando
  • CHU Estaing - Service d'Hématologie Clinique
    Código postal verificado
    Clermont-Ferrand, França· Ainda não recrutando
  • Hôpital Claude Huriez - Service de Médecine Interne
    Código postal verificado
    Lille, France· Ainda não recrutando
  • CHU Nantes - Hôtel Dieu - Service d'Hématologie Clinique
    Código postal verificado
    Nantes, França· Ainda não recrutando
  • Hôpital Saint Louis - Service hématologie séniors
    Código postal verificado
    Paris, França· Ainda não recrutando
  • Hôpital Saint-Antoine - Service de Médecine Interne
    Código postal verificado
    Paris, França· Ainda não recrutando
  • CHU de Haut-Lévèque - Centre F. Magendie - Service des Maladies du sang
    Código postal verificado
    Pessac, França· Ainda não recrutando
  • CH Lyon sud - Service d'Hématologie Clinique
    Código postal verificado
    Pierre-Bénite, France· Recrutamento
  • Hôpital Pontchaillou Service d'hématologie clinique et service de médecine interne
    Código postal verificado
    Rennes, França· Ainda não recrutando
  • IUCT Oncopole Département d'hématologie / Unité de médecine interne
    Código postal verificado
    Toulouse, France· Ainda não recrutando
  • CHU de Tours - Hôpital Bretonneau - Service de Médecine Interne
    Código postal verificado
    Tours, France· Ainda não recrutando

Perguntas frequentes

What is VEXAS syndrome?

VEXAS syndrome is a rare condition that causes ongoing inflammation in different parts of the body, often needing steroid treatment.

What is momelotinib?

Momelotinib is a new experimental drug being tested in this study to see if it can help treat VEXAS syndrome and associated blood problems.

Will I still take my usual steroids?

Yes, all patients in the study will continue to take their daily steroid medication as prescribed by their doctor, alongside momelotinib.

Quanto tempo o estudo durará para mim?

The study's length varies by individual; you'll take momelotinib until your symptoms worsen, you stop responding, or your doctor decides to stop it.

Posso sair do estudo a qualquer momento?

Yes, you are free to leave the study at any point, for any reason, and this will not affect your future medical care.

Como saber mais

Maël HEIBLIG, MD

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Momelotinib in VEXAS Syndrome…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.